Ukko
PrivateLast Round
Series C
Jan 8, 2026
Total Funding Raised
$92.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ukko operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series C round in January 2026.
Ukko is a biotechnology company that develops immunity-boosting proteins and novel immunotherapies aimed at treating food allergies and immune-mediated conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ukko Comparables
Compare Ukko with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IgGenix | 75% | |
| Nestlé | 69% | |
| Biolojic Design | 65% |
For institutional investors. Book with your work email.
Ukko Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 8, 2026 | ||||
| Series B | Jan 27, 2021 | ||||
| Series A | Jul 24, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ukko Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fall Line Capital | Series C, Series B |
| Israel Biotech Fund | Series C |
| Skyviews Life Science | Series B |
| TIME Ventures | Series B |
| Khosla Ventures | Series C, Series A, Series B |
| Innovation Endeavors | Series A, Series B |
| PeakBridge | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2026
Grew 17% QoQ, from 58 to 68 employees.
- May 17, 2026
Monthly visitors grew 108% MoM, reaching 2.5K.
For institutional investors. Book with your work email.
Ukko Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ukko's valuation, stock price, and market status.
Is Ukko a public or private company?
Ukko is a private company.
What is the current stock price of Ukko?
Ukko is a private company, so its shares have no public market price. Caplight tracks Ukko's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ukko worth (valuation)?
Valuation information for Ukko is not publicly available.
Can I buy Ukko stock?
Ukko shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ukko's last funding round?
Ukko's most recent funding round was Series C on January 8, 2026.
Who are the main investors in Ukko?
Key investors in Ukko include Israel Biotech Fund, Leaps by Bayer.
Will Ukko IPO soon?
No public IPO plans have been announced for Ukko.
How can I track Ukko secondary market activity?
Caplight tracks bids, offers, and trades in Ukko's shares on secondary markets.